{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:37:04Z","timestamp":1784000224701,"version":"3.55.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bioorg.2022.105642","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:50:38Z","timestamp":1643485838000},"page":"105642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Recent developments in the management of Huntington's disease"],"prefix":"10.1016","volume":"120","author":[{"given":"Shanaika J.","family":"Devadiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali S.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.105642_b0005","first-page":"317","article-title":"On chorea","volume":"26","author":"Huntington","year":"1872","journal-title":"Med. Surg. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/088307389501000112","article-title":"George Huntington and hereditary chorea","volume":"10","author":"Lanska","year":"1995","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.bioorg.2022.105642_b0015","doi-asserted-by":"crossref","unstructured":"Anonymous, George Huntington (1850-1916) and hereditary chorea, JAMA 193 (1965) 680.","DOI":"10.1001\/jama.1965.03090080042014"},{"key":"10.1016\/j.bioorg.2022.105642_b0020","series-title":"Huntington Disease","author":"Ajitkumar","year":"2021"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington's disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000444230","article-title":"Why we still need more research on the epidemiology of Huntington's disease","volume":"46","author":"Sipila","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2217\/nmt-2016-0008","article-title":"The global prevalence of Huntington's disease: a systematic review and discussion","volume":"6","author":"Baig","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"issue":"5940","key":"10.1016\/j.bioorg.2022.105642_b0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.bioorg.2022.105642_b0045","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1021\/jm00074a015","article-title":"Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors","volume":"36","author":"Mueller","year":"1993","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"issue":"5334","key":"10.1016\/j.bioorg.2022.105642_b0060","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1039856218791036","article-title":"Huntington's disease: Neuropsychiatric manifestations of Huntington's disease","volume":"26","author":"Goh","year":"2018","journal-title":"Australas Psychiatry"},{"issue":"10","key":"10.1016\/j.bioorg.2022.105642_b0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.bioorg.2022.105642_b0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molmed.2003.08.006","article-title":"Huntington's disease: a synaptopathy?","volume":"9","author":"Li","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","article-title":"Extrasynaptic NMDA receptor involvement in central nervous system disorders","volume":"82","author":"Parsons","year":"2014","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.bioorg.2022.105642_b0085","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5694\/j.1326-5377.1978.tb131634.x","article-title":"Huntington's disease: the establishment of a national register","volume":"2","author":"Chiu","year":"1978","journal-title":"Med. J. Aust."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","article-title":"Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neuroscientist"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molcel.2004.06.029","article-title":"Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation","volume":"15","author":"Schaffar","year":"2004","journal-title":"Mol. Cell."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0100","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1326-6-71","article-title":"Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction","volume":"6","author":"Giralt","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bioorg.2022.105642_b0110","doi-asserted-by":"crossref","unstructured":"H.L. Paulson, R.L. Albin, Huntington's disease: clinical features and routes to therapy, in: D.C. Lo, R.E. Hughes (Eds.), Neurobiology of Huntington's Disease: Applications to Drug Discovery, Boca Raton (FL), 2011.","DOI":"10.1201\/EBK0849390005-c1"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","article-title":"Huntington's disease-update on treatments","volume":"17","author":"Wyant","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40263-018-0580-y","article-title":"VMAT2 inhibitors in neuropsychiatric disorders","volume":"32","author":"Tarakad","year":"2018","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-013-0219-8","article-title":"Treatment of huntington disease","volume":"15","author":"Videnovic","year":"2013","journal-title":"Curr. Treat Options Neurol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1474-4422(18)30448-4","article-title":"The hunt for better treatments for Huntington's disease","volume":"18","author":"Barker","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine versus deutetrabenazine for huntington's disease: twins or distant cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.bioorg.2022.105642_b0140","unstructured":"B. Merav, H.E. Lukasiewicz, E. Eli, S.T. Wickenberg, A. Kristina, Pridopidine for treating Huntington's disease, Prilenia Neurotherapeutics Ltd. US 20140378508, Israel, 2014."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0145","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","article-title":"Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study","volume":"48","author":"Grachev","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bioorg.2022.105642_b0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/B978-0-12-801893-4.00018-3","article-title":"Motor outcome measures in Huntington disease clinical trials","volume":"144","author":"Reilmann","year":"2017","journal-title":"Handb. Clin. Neurol."},{"issue":"10","key":"10.1016\/j.bioorg.2022.105642_b0160","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/ml2001455","article-title":"The discovery of VX-745: A novel and selective p38a kinase inhibitor","volume":"2","author":"Duffy","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0165","first-page":"273","article-title":"Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38a to reverse synaptic dysfunction in early Alzheimer's disease","volume":"4","author":"Alam","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0170","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000908","article-title":"Laquinimod dampens IL-1beta signaling and Th17-polarizing capacity of monocytes in patients with MS","volume":"8","author":"Engel","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0175","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jnc.13553","article-title":"Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells","volume":"137","author":"Dobson","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2022.105642_b0180","doi-asserted-by":"crossref","first-page":"31652","DOI":"10.1038\/srep31652","article-title":"Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease","volume":"6","author":"Garcia-Miralles","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2022.105642_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the pathogenesis of Huntington's disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"Pt A","key":"10.1016\/j.bioorg.2022.105642_b0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.expneurol.2016.06.008","article-title":"Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons","volume":"283","author":"Ehrnhoefer","year":"2016","journal-title":"Exp. Neurol."},{"issue":"9","key":"10.1016\/j.bioorg.2022.105642_b0195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"P.E.s. group, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1471-4159.2011.07402.x","article-title":"The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity","volume":"119","author":"Crouch","year":"2011","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","author":"H.D.I. Huntington Study Group Reach","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0210","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105642_b0215","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.3390\/jcm9113682","article-title":"Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington's disease patients-A randomized phase 2 clinical trial","volume":"9","author":"Brownstein","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0220","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/13543776.2020.1709444","article-title":"Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present)","volume":"30","author":"Zagorska","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"16","key":"10.1016\/j.bioorg.2022.105642_b0225","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm900521k","article-title":"Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/JCP.0000000000001128","article-title":"Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia","volume":"39","author":"Walling","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","article-title":"Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease","volume":"86","author":"Klivenyi","year":"2003","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2007.00018.x","article-title":"Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent","volume":"13","author":"Chabrier","year":"2007","journal-title":"CNS Drug Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0245","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0306-3623(87)90175-3","article-title":"(+\/-)-1-[[2-(3,4-Dimethoxphenyl)ethyl]amino]-3-(3-methylphenoxy)-2- propanol hydrochloride (bevantolol, NC-1400) as a beta 1-selective adrenoceptor blocker with alpha 1-adrenoceptor blocking activity","volume":"18","author":"Takayanagi","year":"1987","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.bioorg.2022.105642_b0255","doi-asserted-by":"crossref","unstructured":"S.D. Sussmuth, S. Haider, G.B. Landwehrmeyer, R. Farmer, C. Frost, G. Tripepi, C.A. Andersen, M. Di Bacco, C. Lamanna, E. Diodato, L. Massai, D. Diamanti, E. Mori, L. Magnoni, J. Dreyhaupt, K. Schiefele, D. Craufurd, C. Saft, M. Rudzinska, D. Ryglewicz, M. Orth, S. Brzozy, A. Baran, G. Pollio, R. Andre, S.J. Tabrizi, B. Darpo, G. Westerberg, P. Consortium, An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease, Br. J. Clin. Pharmacol. 79 (3) (2015) 465\u2013476.","DOI":"10.1111\/bcp.12512"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bmcl.2017.11.043","article-title":"Breakthroughs in neuroactive steroid drug discovery","volume":"28","author":"Blanco","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2022.105642_b0265","doi-asserted-by":"crossref","first-page":"12196","DOI":"10.1021\/acs.jmedchem.0c00237","article-title":"Adenosine A2A receptor antagonists for cancer immunotherapy","volume":"63","author":"Yu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105642_b0270","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1177\/0271678X17720868","article-title":"Quantification of human brain PDE4 occupancy by GSK356278: A [(11)C](R)-rolipram PET study","volume":"38","author":"van der Aart","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bioorg.2022.105642_b0275","unstructured":"A. Mieville, Phenoxyalkylcarboxylic acid derivatives, Orchimed S. A. US 4058552 (1975)."},{"key":"10.1016\/j.bioorg.2022.105642_b0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","article-title":"PGC-1alpha, mitochondrial dysfunction, and Huntington's disease","volume":"62","author":"Johri","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0285","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1038\/s41598-017-09148-7","article-title":"Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntington's disease","volume":"7","author":"Jesse","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.bioorg.2022.105642_b0290","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0295","doi-asserted-by":"crossref","first-page":"G872","DOI":"10.1152\/ajpgi.00163.2019","article-title":"Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases?","volume":"317","author":"Keely","year":"2019","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0300","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/exnr.2001.7755","article-title":"A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease","volume":"171","author":"Keene","year":"2001","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0305","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pages","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2022.105642_b0310","doi-asserted-by":"crossref","unstructured":"C. Verny, A.C. Bachoud-Levi, A. Durr, C. Goizet, J.P. Azulay, C. Simonin, C. Tranchant, F. Calvas, P. Krystkowiak, P. Charles, K. Youssov, C. Scherer, A. Prundean, A. Olivier, P. Reynier, F. Saudou, P. Maison, P. Allain, E. von Studnitz, D. Bonneau, C.-H.S. Group, A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease, Mov. Disord. 32 (6) (2017) 932\u2013936.","DOI":"10.1002\/mds.27010"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0315","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington's disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145842","article-title":"How to capitalize on the retest effect in future trials on Huntington's disease","volume":"10","author":"Schramm","year":"2015","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0325","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11591280-000000000-00000","article-title":"Clinical and experimental applications of sodium phenylbutyrate","volume":"11","author":"Iannitti","year":"2011","journal-title":"Drugs R. D."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0330","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd1387","article-title":"Atomoxetine hydrochloride","volume":"3","author":"Garland","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0335","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","article-title":"Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies","volume":"53","author":"Michelson","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0340","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","article-title":"Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease","volume":"29","author":"Beglinger","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bioorg.2022.105642_b0345","unstructured":"J.H. Boothe, J. Petisi, Reductive alkylation of tetracycline amines, American Cyanamid Co. US 3148212, USA, 1961."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0350","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","article-title":"Minocycline safety and tolerability in Huntington disease","volume":"63","author":"G. Huntington Study","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.bioorg.2022.105642_b0355","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2022.105642_b0360","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fpsyt.2019.00221","article-title":"Sleep disorders in Huntington's disease","volume":"10","author":"Herzog-Krzywoszanska","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0365","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and Dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0370","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0375","first-page":"1582","article-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study","volume":"65","author":"T.-H.D.I. Huntington Study Group","year":"2008","journal-title":"Arch Neurol."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0380","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0385","first-page":"328","article-title":"Valbenazine (Ingrezza): The first FDA-approved treatment for tardive dyskinesia","volume":"43","author":"Uhlyar","year":"2018","journal-title":"P. T."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jimd.12313","article-title":"Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study","volume":"44","author":"Vockley","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0395","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0400","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"2\u20134","key":"10.1016\/j.bioorg.2022.105642_b0405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/biof.5520090222","article-title":"Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases","volume":"9","author":"Beal","year":"1999","journal-title":"Biofactors"},{"issue":"Pt 1","key":"10.1016\/j.bioorg.2022.105642_b0410","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.bioorg.2022.105642_b0415","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"J. Neurol."},{"issue":"18","key":"10.1016\/j.bioorg.2022.105642_b0420","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0425","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.26003","article-title":"Plasma melatonin is reduced in Huntington's disease","volume":"29","author":"Kalliolia","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0430","first-page":"303","article-title":"Gene-selective treatment approaches for Huntington's disease","volume":"91","author":"Muhlback","year":"2020","journal-title":"Nervenarzt"},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0435","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaneurol.2020.0299","article-title":"Huntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks","volume":"77","author":"Leavitt","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bioorg.2022.105642_b0440","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0445","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000367","article-title":"Safety\/tolerability of the anti-semaphorin 4D Antibody VX15\/2503 in a randomized phase 1 trial","volume":"4","author":"LaGanke","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0450","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/1535-7163.MCT-14-0924","article-title":"Nonclinical safety evaluation of VX15\/2503, a humanized IgG4 anti-SEMA4D antibody","volume":"14","author":"Leonard","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2022.105642_b0455","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.170","article-title":"Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-kappaB pathway","volume":"4","author":"Hyrskyluoto","year":"2013","journal-title":"Cell Death Dis."},{"issue":"Pt A","key":"10.1016\/j.bioorg.2022.105642_b0460","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"7600","key":"10.1016\/j.bioorg.2022.105642_b0465","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human sigma1 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0470","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng1534","article-title":"Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons","volume":"37","author":"Parker","year":"2005","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","article-title":"Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway","volume":"18","author":"Jeong","year":"2011","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0480","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","article-title":"Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets","volume":"18","author":"Jiang","year":"2011","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150682","article-title":"Correction: SIRT1 activity is linked to its brain region-specific phosphorylation and is impaired in Huntington's disease mice","volume":"11","author":"Tulino","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2022.105642_b0490","article-title":"SIRT1 and SIRT2 activity control in neurodegenerative diseases","volume":"11","author":"Manjula","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.bioorg.2022.105642_b0495","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum. Mol. Genet."},{"issue":"25","key":"10.1016\/j.bioorg.2022.105642_b0500","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1021\/jm050522v","article-title":"Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1","volume":"48","author":"Napper","year":"2005","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105642_b0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","article-title":"A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease","volume":"23","author":"Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0510","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/jm301431y","article-title":"The 2.5 A crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition","volume":"56","author":"Zhao","year":"2013","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0515","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal Ganglia function in Huntington's disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.114.214155","article-title":"GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species","volume":"350","author":"Rutter","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0525","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"issue":"20","key":"10.1016\/j.bioorg.2022.105642_b0530","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1523\/JNEUROSCI.22-20-09122.2002","article-title":"The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity","volume":"22","author":"Blum","year":"2002","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0535","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0512","article-title":"Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease","volume":"10","author":"Blum","year":"2002","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0540","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.pharep.2014.07.006","article-title":"Improvement of mitochondrial NAD(+)\/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease","volume":"66","author":"Mishra","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2022.105642_b0545","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2013.05.013","article-title":"Association between caffeine intake and age at onset in Huntington\u2019s disease","volume":"58","author":"Simonin","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2022.105642_b0550","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Res."},{"issue":"7511","key":"10.1016\/j.bioorg.2022.105642_b0555","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature13396","article-title":"Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain","volume":"511","author":"Dore","year":"2014","journal-title":"Nature"},{"issue":"5905","key":"10.1016\/j.bioorg.2022.105642_b0560","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bioorg.2022.105642_b0565","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00415-012-6428-3","article-title":"Positron emission tomography imaging in neurological disorders","volume":"259","author":"Politis","year":"2012","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0570","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","article-title":"Neuroimaging in Huntington's disease","volume":"6","author":"Niccolini","year":"2014","journal-title":"World J. Radiol."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0575","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2022.105642_b0580","doi-asserted-by":"crossref","first-page":"10345","DOI":"10.1021\/acs.jmedchem.7b01922","article-title":"Why are the majority of active compounds in the CNS domain natural products? A critical analysis","volume":"61","author":"Bharate","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0585","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0590","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/jpet.110.172882","article-title":"Phenyl ring-substituted lobelane analogs: inhibition of [(3)H]dopamine uptake at the vesicular monoamine transporter-2","volume":"336","author":"Nickell","year":"2011","journal-title":"J.Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2022.105642_b0595","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2022.105642_b0600","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","article-title":"Deutetrabenazine for the treatment of Huntington\u2019s chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert Rev. Neurother."},{"issue":"10","key":"10.1016\/j.bioorg.2022.105642_b0605","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1016\/j.ejmech.2011.08.008","article-title":"Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands","volume":"46","author":"Joubert","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0610","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bmcl.2008.09.012","article-title":"Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics","volume":"19","author":"von Coburg","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2022.105642_b0615","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1021\/jm400181k","article-title":"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective sigma1 receptor ligands","volume":"56","author":"Diaz","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0620","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(79)90052-9","article-title":"Species variation in dopamine receptor binding","volume":"60","author":"Creese","year":"1979","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0625","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.npp.1300057","article-title":"Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders","volume":"28","author":"Marek","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0630","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1254\/jjp.41.419","article-title":"Comparison of effects of tiapride and sulpiride on D-1, D-2, D-3 and D-4 subtypes of dopamine receptors in rat striatal and bovine caudate nucleus membranes","volume":"41","author":"Arima","year":"1986","journal-title":"Jpn. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0635","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2013too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"issue":"18","key":"10.1016\/j.bioorg.2022.105642_b0640","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0024-3205(97)00126-4","article-title":"D1 dopamine receptor activity of anti-parkinsonian drugs","volume":"60","author":"Fici","year":"1997","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0645","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bmcl.2012.11.023","article-title":"Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D2 partial agonists","volume":"23","author":"Urbanek","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0650","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105642_b0655","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1021\/jm100294b","article-title":"Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors","volume":"53","author":"Butini","year":"2010","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0660","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","article-title":"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity","volume":"95","author":"Gillman","year":"2005","journal-title":"Br. J. Anaesth."},{"issue":"18","key":"10.1016\/j.bioorg.2022.105642_b0665","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1016\/j.bmcl.2010.07.105","article-title":"Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands","volume":"20","author":"Krogsgaard-Larsen","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2022.105642_b0670","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0675","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0680","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105642_b0685","first-page":"350","article-title":"Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"28","author":"Owens","year":"2002","journal-title":"Encephale"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105642_b0690","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1124\/jpet.105.094474","article-title":"Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?","volume":"316","author":"Mirza","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105642_b0695","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0028-3908(86)90214-5","article-title":"Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes","volume":"25","author":"Larsson","year":"1986","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0700","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bmc.2012.10.045","article-title":"Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase","volume":"21","author":"Catto","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2022.105642_b0705","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.bmc.2013.01.052","article-title":"Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors","volume":"21","author":"Imramovsky","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105642_b0710","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nbd.2018.08.010","article-title":"A role for autophagy in Huntington's disease","volume":"122","author":"Croce","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.bioorg.2022.105642_b0715","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.jmb.2019.11.012","article-title":"Lowering mutant huntingtin levels and toxicity: autophagy-endolysosome pathways in Huntington's disease","volume":"432","author":"Valionyte","year":"2020","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0720","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: a potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.bioorg.2022.105642_b0725","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41401-020-00605-0","article-title":"Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP\/p97-LC3-mHTT complex","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105642_b0730","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acschemneuro.8b00516","article-title":"SQSTM1\/p62: a potential target for neurodegenerative disease","volume":"10","author":"Ma","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105642_b0735","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/brain\/awz400","article-title":"Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in neurodegeneration","volume":"143","author":"Iturria-Medina","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105642_b0740","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12920-020-00822-w","article-title":"Identification of contributing genes of Huntington's disease by machine learning","volume":"13","author":"Cheng","year":"2020","journal-title":"BMC Med. Genomics"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:28:07Z","timestamp":1758616087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":148,"alternative-id":["S0045206822000475"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105642","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments in the management of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105642"}}